Cargando…

The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease

PURPOSE: Indoxyl sulfate (IS) is one of the most potent uremic toxins involved in chronic kidney disease (CKD) progression, induction of inflammation, oxidative stress, and cardiovascular diseases occurrence. It is proved that hypertension is a common CVD complication and a major death risk factor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaminski, Tomasz W., Pawlak, Krystyna, Karbowska, Malgorzata, Znorko, Beata, Mor, Adrian L., Mysliwiec, Michal, Pawlak, Dariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424951/
https://www.ncbi.nlm.nih.gov/pubmed/30617956
http://dx.doi.org/10.1007/s11255-018-02064-3
_version_ 1783404751478587392
author Kaminski, Tomasz W.
Pawlak, Krystyna
Karbowska, Malgorzata
Znorko, Beata
Mor, Adrian L.
Mysliwiec, Michal
Pawlak, Dariusz
author_facet Kaminski, Tomasz W.
Pawlak, Krystyna
Karbowska, Malgorzata
Znorko, Beata
Mor, Adrian L.
Mysliwiec, Michal
Pawlak, Dariusz
author_sort Kaminski, Tomasz W.
collection PubMed
description PURPOSE: Indoxyl sulfate (IS) is one of the most potent uremic toxins involved in chronic kidney disease (CKD) progression, induction of inflammation, oxidative stress, and cardiovascular diseases occurrence. It is proved that hypertension is a common CVD complication and a major death risk factor as well as contributes for decline in a renal function. The aim of our study was to investigate how implementing of antihypertensive therapy impact IS concentrations and the associations between IS and markers of renal function, inflammation and oxidative stress. METHODS: Study was conducted on 50 patients diagnosed with CKD and hypertension, divided into three groups: without hypotensive therapy (CKD-NONE), hypotensive monotherapy (CKD-MONO), and hypotensive polypharmacotherapy (CKD-POLI), and 18 healthy volunteers. The markers of inflammation [interleukin-6, tumor necrosis factor-alpha (TNF-α), high-sensitive C-reactive protein (hs-CRP), neopterin, ferritin], oxidative status [superoxide dismutase (Cu/Zn-SOD), antibodies against oxidized low-density lipoprotein (oxLDL-abs)], and selectins were determinate using immunoenzymatic methods. IS levels were assayed using high-performance liquid chromatography and other parameters were analysed using routine laboratory techniques. Then cross-sectional analysis was performed. RESULTS: Elevated levels of IS, indicators of kidney function, markers of inflammation and blood pressure values were observed in each CKD subgroups. There was no effect of antihypertensive therapy on IS levels between studied groups, as well as there was no clear relationship between IS and blood pressure values in each studied group. The positive associations between IS and Cu/Zn SOD, neopterin, hs-CRP, creatinine and neutrophils/lymphocytes ratio were observed in CKD-NONE and CKD-POLI subgroups. Additionally, in CKD-POLI group IS positively correlated with TNF-α, ferritin and neutrophils. In CKD-MONO group, IS was positively related to oxLDL-abs, neopterin, E-selectin and creatinine, whereas it was inversely associated with hs-CRP. CONCLUSIONS: Our study showed for the first time that the antihypertensive therapy has no impact on IS levels in CKD patients with hypertension. However, the introduction of the antihypertensive therapy modified the dependencies between IS and the studied markers of kidney function, inflammation, oxidative stress and hematological parameters that are crucial for mortality and morbidity amongst the CKD patients with hypertension. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11255-018-02064-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6424951
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-64249512019-04-05 The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease Kaminski, Tomasz W. Pawlak, Krystyna Karbowska, Malgorzata Znorko, Beata Mor, Adrian L. Mysliwiec, Michal Pawlak, Dariusz Int Urol Nephrol Nephrology - Original Paper PURPOSE: Indoxyl sulfate (IS) is one of the most potent uremic toxins involved in chronic kidney disease (CKD) progression, induction of inflammation, oxidative stress, and cardiovascular diseases occurrence. It is proved that hypertension is a common CVD complication and a major death risk factor as well as contributes for decline in a renal function. The aim of our study was to investigate how implementing of antihypertensive therapy impact IS concentrations and the associations between IS and markers of renal function, inflammation and oxidative stress. METHODS: Study was conducted on 50 patients diagnosed with CKD and hypertension, divided into three groups: without hypotensive therapy (CKD-NONE), hypotensive monotherapy (CKD-MONO), and hypotensive polypharmacotherapy (CKD-POLI), and 18 healthy volunteers. The markers of inflammation [interleukin-6, tumor necrosis factor-alpha (TNF-α), high-sensitive C-reactive protein (hs-CRP), neopterin, ferritin], oxidative status [superoxide dismutase (Cu/Zn-SOD), antibodies against oxidized low-density lipoprotein (oxLDL-abs)], and selectins were determinate using immunoenzymatic methods. IS levels were assayed using high-performance liquid chromatography and other parameters were analysed using routine laboratory techniques. Then cross-sectional analysis was performed. RESULTS: Elevated levels of IS, indicators of kidney function, markers of inflammation and blood pressure values were observed in each CKD subgroups. There was no effect of antihypertensive therapy on IS levels between studied groups, as well as there was no clear relationship between IS and blood pressure values in each studied group. The positive associations between IS and Cu/Zn SOD, neopterin, hs-CRP, creatinine and neutrophils/lymphocytes ratio were observed in CKD-NONE and CKD-POLI subgroups. Additionally, in CKD-POLI group IS positively correlated with TNF-α, ferritin and neutrophils. In CKD-MONO group, IS was positively related to oxLDL-abs, neopterin, E-selectin and creatinine, whereas it was inversely associated with hs-CRP. CONCLUSIONS: Our study showed for the first time that the antihypertensive therapy has no impact on IS levels in CKD patients with hypertension. However, the introduction of the antihypertensive therapy modified the dependencies between IS and the studied markers of kidney function, inflammation, oxidative stress and hematological parameters that are crucial for mortality and morbidity amongst the CKD patients with hypertension. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11255-018-02064-3) contains supplementary material, which is available to authorized users. Springer Netherlands 2019-01-07 2019 /pmc/articles/PMC6424951/ /pubmed/30617956 http://dx.doi.org/10.1007/s11255-018-02064-3 Text en © The Author(s) 2019 OpenAccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Nephrology - Original Paper
Kaminski, Tomasz W.
Pawlak, Krystyna
Karbowska, Malgorzata
Znorko, Beata
Mor, Adrian L.
Mysliwiec, Michal
Pawlak, Dariusz
The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
title The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
title_full The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
title_fullStr The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
title_full_unstemmed The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
title_short The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
title_sort impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
topic Nephrology - Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424951/
https://www.ncbi.nlm.nih.gov/pubmed/30617956
http://dx.doi.org/10.1007/s11255-018-02064-3
work_keys_str_mv AT kaminskitomaszw theimpactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT pawlakkrystyna theimpactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT karbowskamalgorzata theimpactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT znorkobeata theimpactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT moradrianl theimpactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT mysliwiecmichal theimpactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT pawlakdariusz theimpactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT kaminskitomaszw impactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT pawlakkrystyna impactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT karbowskamalgorzata impactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT znorkobeata impactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT moradrianl impactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT mysliwiecmichal impactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease
AT pawlakdariusz impactofantihypertensivepharmacotherapyoninterplaybetweenproteinbounduremictoxinindoxylsulfateandmarkersofinflammationinpatientswithchronickidneydisease